Tangshen formula (
TSF), a well-prescribed traditional Chinese formula, has been used in the treatment of
diabetic nephropathy. However, whether
TSF ameliorates
dyslipidemia and liver injury associated with diabetes remains unclear. In this study, we examined the effects of
TSF on
lipid profiles and hepatic steatosis in db/db mice. For this purpose, 8‑week-old db/db mice were treated with
TSF or saline for 12 weeks via gavage and db/m mice were used as controls.
Body weight and
blood glucose levels were monitored weekly and bi-weekly, respectively. Blood samples were obtained for the analysis of
lipids and
enzymes related to hepatic function, and liver tissues were analyzed by histology, immunohistochemistry and molecular examination. The results revealed that
TSF markedly reduced
body weight, liver index [liver/body weight (LW/BW)] and improved
lipid profiles, hepatic function and steatosis in db/db mice.
TSF induced the phosphoralation of
AMP-activated protein kinase and inhibited the activity of
sterol regulatory
element-binding protein 1 together with the inhibition of the expression of genes involved in de novo lipogenesis (DNL) and gluconeogenesis, such as
fatty acid synthase (FAS), acetyl-CoA carboxylase (ACC), stearoyl CoA desaturase 1 (SCD1), glucose-6-phosphatase (G6pc) and
phosphoenolpyruvate carboxykinase 1 (Pck1). Additionally, the silent mating type information regulation 2 homolog 1 (
Sirt1)/peroxisome proliferator-activated receptor α (PPARα)/
malonyl-CoA decarboxylase (MLYCD) cascade was potently activated by
TSF in the liver and skeletal muscle of db/db mice, which led to enhanced
fatty acid oxidation. These findings demonstrated that
TSF attenuated hepatic fat accumulation and steatosis in db/db mice by inhibiting lipogenesis and augmenting
fatty acid oxidation.